<h4>Background</h4>The BRAF V600E mutation is a rare genetic alteration in cholangiocarcinoma for which sequential therapy with immune checkpoint inhibitors (ICIs) and BRAF/MEK inhibitors may be effective. This evidence concerns the gene BRAF and cholangiocarcinoma.